You are here

Postlicensure Observational Safety Study of 13vPnC Administered to Infants and Toddlers

Last updated on February 28, 2019

FOR MORE INFORMATION
Study Location
Northern California Kaiser Permanente
Oakland, California, 94612 United States
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Pneumococcal Disease
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
2-3 months
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Infants starting vaccination with 13vPnC in the first 6 months of life who are members
of the Northern California Kaiser Permanente healthcase system and who receive at
least 1 dose of 13vPnC during the study observation period will be included. Infants
must not have had 7vPnC at the time of 13vPnC dose administration.

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Infants and children who were previously vaccinated with any number of doses of 7vPnC
will be excluded.

NCT01128426
Pfizer
Completed
Postlicensure Observational Safety Study of 13vPnC Administered to Infants and Toddlers

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]

Call Now